ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 258 filers reported holding ACCELERON PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $18,432,000 | +92.5% | 107,102 | +40.4% | 0.01% | +100.0% |
| Q2 2021 | $9,573,000 | -17.3% | 76,284 | -10.6% | 0.00% | -25.0% |
| Q1 2021 | $11,578,000 | +3.1% | 85,372 | -2.8% | 0.00% | 0.0% |
| Q4 2020 | $11,232,000 | +17.5% | 87,787 | +3.4% | 0.00% | 0.0% |
| Q3 2020 | $9,558,000 | +6.7% | 84,940 | -9.6% | 0.00% | 0.0% |
| Q2 2020 | $8,955,000 | -27.9% | 93,991 | -32.0% | 0.00% | -33.3% |
| Q1 2020 | $12,426,000 | +16.2% | 138,273 | -31.5% | 0.01% | +50.0% |
| Q4 2019 | $10,697,000 | +14.4% | 201,759 | -14.8% | 0.00% | 0.0% |
| Q3 2019 | $9,354,000 | +24.5% | 236,744 | +29.5% | 0.00% | +33.3% |
| Q2 2019 | $7,512,000 | +1.8% | 182,847 | +15.4% | 0.00% | 0.0% |
| Q1 2019 | $7,380,000 | -36.4% | 158,473 | -40.6% | 0.00% | -40.0% |
| Q4 2018 | $11,609,000 | +2.9% | 266,575 | +35.2% | 0.01% | +25.0% |
| Q3 2018 | $11,285,000 | +20.9% | 197,188 | +2.5% | 0.00% | 0.0% |
| Q2 2018 | $9,336,000 | -14.7% | 192,413 | -31.3% | 0.00% | -20.0% |
| Q1 2018 | $10,944,000 | +63.0% | 279,883 | +76.9% | 0.01% | +66.7% |
| Q4 2017 | $6,714,000 | +11.9% | 158,201 | -1.6% | 0.00% | 0.0% |
| Q3 2017 | $6,002,000 | +86.2% | 160,830 | +51.7% | 0.00% | +50.0% |
| Q2 2017 | $3,223,000 | +147.9% | 106,050 | +115.9% | 0.00% | +100.0% |
| Q1 2017 | $1,300,000 | -10.8% | 49,123 | -14.0% | 0.00% | 0.0% |
| Q4 2016 | $1,457,000 | +10.3% | 57,090 | +56.4% | 0.00% | 0.0% |
| Q3 2016 | $1,321,000 | -7.4% | 36,511 | -13.0% | 0.00% | 0.0% |
| Q2 2016 | $1,427,000 | +43.4% | 41,975 | +11.3% | 0.00% | 0.0% |
| Q1 2016 | $995,000 | -52.8% | 37,701 | -12.8% | 0.00% | 0.0% |
| Q4 2015 | $2,108,000 | +135.0% | 43,229 | +20.0% | 0.00% | 0.0% |
| Q3 2015 | $897,000 | +3488.0% | 36,017 | +4402.1% | 0.00% | – |
| Q2 2015 | $25,000 | -37.5% | 800 | -24.0% | 0.00% | – |
| Q1 2015 | $40,000 | – | 1,053 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |